Celgene's Revlimid, a treatment for blood cancer, may have caused 14 cases of Stevens-Johnson syndrome, a rare but serious skin reaction also known as toxic epidermal necrolysis, the FDA said on its Web site. The finding is based on the agency's postmarketing safety review of Revlimid, which was approved in December 2005.

Related Summaries